Thursday, August 6, 2015

AASLD/IDSA Guidlines Updated: When and In Whom to Initiate Therapy

The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) with the International Antiviral Society developed a living document with ever evolving guidelines to treat HCV.

The new guidelines have a complex algorithm for practitioners around the country to follow and see whats the right right treatment, for the right patients, for the right about of time. The document is patient friendly, which benefit patients living with or considering HCV therapy. 

When new HCV drugs are approved, and new real world data is established, the guidelines are updated.

Guidance Sections Updated

The When and In Whom to Initiate TherapyInitial TreatmentRetreatmentAcute HCV Infection, and Unique Populations (HIV/HCV CoinfectionDecompensated Cirrhosis, and Renal Impairment) sections have been updated to reflect newly available data presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2015.

HCV Guidance is available as an "Accepted Article" in HEPATOLOGY

Article first published online: 4 AUG 2015

Full Text
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
The pace of hepatitis C virus (HCV) drug development in recent years has accelerated dramatically. For patients to benefit from these impressive advances, practitioners need access to the most up-to-date data and to advice from experienced experts. Such information and advice can be difficult to access readily given the diverse sources from which information is available and the sometimes lengthy time needed for publication of original articles and scholarly perspectives. Traditional practice guidelines for more established areas of medicine and care often take years to develop and bring to publication. In the new era in hepatitis C treatment, such a process would not be nimble or timely enough to address the needs of patients with HCV infection, practitioners caring for these patients, or payers approving therapies for use. A living document made available in a web-based system, such as that used by the US Department of Health and Human Services for human immunodeficiency virus (HIV) treatment recommendations (, was selected as the best model to provide timely recommendations for hepatitis C management. In 2013, the two major membership societies supporting liver and infectious disease specialists (American Association for the Study of Liver Diseases [AASLD] and Infectious Diseases Society of America [IDSA]) joined forces to develop guidance for the management of hepatitis C in this rapidly moving field. The International Antiviral Society-USA, which has experience in developing treatment guidelines in HIV disease, was invited to join the effort as a collaborating partner responsible for managing the panel and the guidance development process.

The goal of the hepatitis C guidance is to provide up-to-date recommendations for HCV care practitioners on the optimal screening, management, and treatment for adults with HCV infection in the United States, using a rigorous review process to evaluate the best available evidence. This review provides a condensed summary of recommendations from the guidance. The complete guidance, which is updated regularly, is available at

Continue to HEPATOLOGY...

No comments:

Post a Comment